Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma.

Deepa JagadeeshSteve HorwitzNancy L BartlettYoun KimEric JacobsenMadeleine DuvicMeredith LittleWilliam TrepicchioKeenan FentonMatthew OnsumJulie LisanoRanjana Advani

Published in: The oncologist (2022)

In this analysis of studies across a range of CD30-expressing lymphomas, CD30 expression alone, as measured by standard IHC, does not predict clinical benefit from BV, making the determination of a threshold level of expression uncertain.

Keyphrases

poor prognosis
binding protein
long non coding rna
nk cells
lps induced
molecularly imprinted